High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India

AIDS Research and Human Retroviruses

Volumn 23, Issue 10, 2007, Pages 1303-1308

  Sen, Sourav ^a   Tripathy, Srikanth P ^b   Patil, Ajit A ^b   Chimanpure, Vaishali M ^b   Paranjape, Ramesh S ^b  

^a Command Hospital ^*  (India)

^b NATIONAL AIDS RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; DNA SEQUENCE; DRUG TREATMENT FAILURE; GENETIC ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INDIA; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIROLOGY; VIRUS MUTATION; VIRUS RESISTANCE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; GENES, POL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDIA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 35549011985     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0090     Document Type: Article

References (21)

1. World Health Organization 2005: Summary country profile for HIV/AIDS treatment scale-up. Available at http://www.who.int/3by5/support/june2005_ind. pdf. Accessed on 18 January 2007.
2. Shafer RW: Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15(2):247-277.
3. Sarmati L, Nicastri E, Uccella I, et al.: Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing. J Clin Microbiol 2003;41(4):1760-1762.
4. Turriziani O, Bucci M, Stano A, et al.: Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr 2007;44(5):518-524.
5. Sen S, Tripathy SP, Chimanpure VM, Patil AA, Bagul RD, and Paranjape RS: Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment naive and treatment experienced patients from Pune, India. AIDS Res Hum Retroviruses 2007;23(4):489-497.
6. Brehm J, Koontz D, Pathak V, Sluis-Cremer N, and Mellors J: AZT selects mutations in the connection (A371V) and RNase H (Q509L) domains of RT that increase AZT resistance in combination with TAMs and reduce susceptibility to other NRTIs. Antiviral Ther 2006;11:S141.
7. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al.: Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci USA 2007;104(1):317-322.
8. Gupta S, Fransen S, Paxinos EE, et al.: Infrequent occurrence of mutations in the C-terminal region of reverse transcriptase modulates susceptibility to RT inhibitors. Antiviral Ther 2006;11:S143.
9. Marcelin AG, Delaugerre C, Wirden M, et al.: Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004;72(1):162-165.
10. Yahi N, Tamalet C, Tourres C, et al.: Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences. J Clin Microbiol 1999;37(12):4099-4106.
11. Hanna GJ, Johnson VA, Kuritzkes DR, et al.: Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000;181(3):904-911.
12. Shet A, Berry L, Mohri H, et al.: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 2006;41(4):439-446.
13. Shafer RW, Rhee SY, Pillay D, et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21(2):215-223.
14. Parikh UM, Bacheler L, Koontz D, and Mellors JW: The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006;80(10):4971-4977.
15. Eshleman SH, Hudelson SE, Gupta A, et al.: Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India. AIDS Res Hum Retroviruses 2005;21(1):93-97.
16. Balakrishnan P, Kumarasamy N, Kantor R, et al.: HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses 2005;21(4):301-305.
17. Deshpande A, Recordon-Pinson P, Deshmukh R, et al.: Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS Res Hum Retroviruses 2004;20(9):1032-1035.
18. Deshpande A, Jauvin V, Magnin N, et al.: Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: Resistance to AR. AIDS Res Hum Retroviruses 2007;23(2):335-340.
19. Bennett DE, Winters MA, Shafer RW, et al.: Concordance of HIV drug resistance genotyping results for paired PBMC and plasma specimens from persons newly diagnosed with HIV. Antiviral Ther 2005;10:S176.
20. Devereux HL, Loveday C, Youle M, Sabin CA, Burke A, and Johnson M: Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. AIDS Res Hum Retroviruses 2000;16(11):1025-1030.
21. Chew CB, Potter SJ, Wang B, et al.: Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 2005;33(3):206-216.